Macitentan/Tadalafil FDC

Phase 3Small molecule

Macitentan/Tadalafil FDC is one of 5 small molecule programs targeting Hypertension, Pulmonary. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hypertension, PulmonaryRecruiting

Hypertension, PulmonaryPhase 3

Recruiting

Competition

Competitive Landscape

5 competitors in Hypertension, Pulmonary

#DrugCompanyPhaseTrials

Adempas

Bayer

Phase 3

2 2

Uptravi

Johnson & Johnson

Phase 3

2 3

Opsumit

Johnson & Johnson

Phase 3

1 4

Winrevair

Merck & Co.

Phase 2

1 5

Macitentan/Tadalafil FDC

Johnson & Johnson

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 3Recruiting

Hypertension, Pulmonary

NCT05179876

Clinical

Trials by Indication[1]

Hypertension, Pulmonary1 trial

A Prospective, Open-label, Platform Study for Long-term Follow-up of Participants Using Study Intervention in Pulmonary Hypertension Parent Studies

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT05179876·280 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Macitentan/Tadalafil FDC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Macitentan/Tadalafil FDC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Macitentan/Tadalafil FDC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Macitentan/Tadalafil FDC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Hypertension, Pulmonary1 trial

References

Drug Info

Quick Facts

Related News